NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
Celgene
Wake Forest University Health Sciences
Massachusetts General Hospital
Roswell Park Cancer Institute
Weill Medical College of Cornell University
University of Chicago